UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 78 filers reported holding UROGEN PHARMA LTD in Q1 2020. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $343,245 | +35.4% | 24,500 | 0.0% | 0.03% | +60.0% |
| Q2 2023 | $253,575 | +12.0% | 24,500 | 0.0% | 0.02% | +5.3% |
| Q1 2023 | $226,380 | +4.2% | 24,500 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $217,315 | +6.5% | 24,500 | 0.0% | 0.02% | +18.8% |
| Q3 2022 | $204,000 | +1.5% | 24,500 | 0.0% | 0.02% | -11.1% |
| Q2 2022 | $201,000 | -5.6% | 24,500 | 0.0% | 0.02% | +12.5% |
| Q1 2022 | $213,000 | -8.6% | 24,500 | 0.0% | 0.02% | +6.7% |
| Q4 2021 | $233,000 | -43.4% | 24,500 | 0.0% | 0.02% | -40.0% |
| Q3 2021 | $412,000 | +10.2% | 24,500 | 0.0% | 0.02% | +19.0% |
| Q2 2021 | $374,000 | -21.6% | 24,500 | 0.0% | 0.02% | -22.2% |
| Q1 2021 | $477,000 | +8.2% | 24,500 | 0.0% | 0.03% | +17.4% |
| Q4 2020 | $441,000 | -6.8% | 24,500 | 0.0% | 0.02% | -11.5% |
| Q3 2020 | $473,000 | -26.1% | 24,500 | 0.0% | 0.03% | -31.6% |
| Q2 2020 | $640,000 | +46.5% | 24,500 | 0.0% | 0.04% | +2.7% |
| Q1 2020 | $437,000 | – | 24,500 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |